Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug
Both Co-Primary Endpoints Hit In TRANQUILITY-2
The company plans to submit an NDA for reproxalap for dry eye disease based on the results and hailed the crossover trial design as unique in the therapeutic area.
